92 related articles for article (PubMed ID: 11816473)
1. [Tumor markers in malignant lymphoma].
Banno S; Ueda R
Gan To Kagaku Ryoho; 2002 Jan; 29(1):149-53. PubMed ID: 11816473
[TBL] [Abstract][Full Text] [Related]
2. [Tumor markers in malignant lymphoma].
Kato H; Ogura M
Gan To Kagaku Ryoho; 2005 Jun; 32(6):883-92. PubMed ID: 15984537
[TBL] [Abstract][Full Text] [Related]
3. Morphologic diagnosis of leukaemic B-lymphoproliferative disorders and the role of cyclin D1 expression.
Oertel J; Kingreen D; Busemann C; Stein H; Dörken B
J Cancer Res Clin Oncol; 2002 Apr; 128(4):182-8. PubMed ID: 11935308
[TBL] [Abstract][Full Text] [Related]
4. Cyclin B1 expression is an independent prognostic marker for poor outcome in diffuse large B-cell lymphoma.
Obermann EC; Went P; Pehrs AC; Tzankov A; Wild PJ; Pileri S; Hofstaedter F; Dirnhofer S
Oncol Rep; 2005 Dec; 14(6):1461-7. PubMed ID: 16273239
[TBL] [Abstract][Full Text] [Related]
5. Reduced or absent cyclin H expression is an independent prognostic marker for poor outcome in diffuse large B-cell lymphoma.
Bavi P; Abubaker J; Hussain A; Sultana M; Al-Dayel F; Uddin S; Al-Kuraya KS
Hum Pathol; 2008 Jun; 39(6):885-94. PubMed ID: 18400256
[TBL] [Abstract][Full Text] [Related]
6. Serum soluble interleukin-2 receptor, beta2-microglobulin, lactate dehydrogenase and erythrocyte sedimentation rate in children with Hodgkin's lymphoma.
Bien E; Balcerska A
Scand J Immunol; 2009 Nov; 70(5):490-500. PubMed ID: 19874554
[TBL] [Abstract][Full Text] [Related]
7. Serum-soluble tumor necrosis factor receptor 2 (sTNF-R2) level determines clinical outcome in patients with aggressive non-Hodgkin's lymphoma.
Goto N; Tsurumi H; Takemura M; Hara T; Sawada M; Kasahara S; Kanemura N; Yamada T; Shimizu M; Takahashi T; Tomita E; Seishima M; Takami T; Moriwaki H
Eur J Haematol; 2006 Sep; 77(3):217-25. PubMed ID: 16856931
[TBL] [Abstract][Full Text] [Related]
8. Molecular control of the cell cycle in cancer: biological and clinical aspects.
Møller MB
Dan Med Bull; 2003 May; 50(2):118-38. PubMed ID: 12812137
[TBL] [Abstract][Full Text] [Related]
9. Hypermethylation of CpG islands in p16 as a prognostic factor for diffuse large B-cell lymphoma in a high-risk group.
Shiozawa E; Takimoto M; Makino R; Adachi D; Saito B; Yamochi-Onizuka T; Yamochi T; Shimozuma J; Maeda T; Kohno Y; Kawakami K; Nakamaki T; Tomoyasu S; Shiokawa A; Ota H
Leuk Res; 2006 Jul; 30(7):859-67. PubMed ID: 16406514
[TBL] [Abstract][Full Text] [Related]
10. Malignant non-Hodgkin's lymphoma of childhood and adolescence in Austria--therapy results between 1986 and 2000.
Attarbaschi A; Mann G; Dworzak M; Trebo M; Urban C; Fink FM; Horcher E; Reiter A; Riehm H; Gadner H;
Wien Klin Wochenschr; 2002 Dec; 114(23-24):978-86. PubMed ID: 12635465
[TBL] [Abstract][Full Text] [Related]
11. Diagnostic and prognostic significance of gene expression profiling in lymphomas.
Leich E; Hartmann EM; Burek C; Ott G; Rosenwald A
APMIS; 2007 Oct; 115(10):1135-46. PubMed ID: 18042147
[TBL] [Abstract][Full Text] [Related]
12. Catalyzed signal amplification for cyclin D1 detection in mantle cell lymphoma.
Barranco C; Mate JL; Ariza A; Baró T; Díaz E; Munné A; Serrano S
Mod Pathol; 2003 Feb; 16(2):161-5. PubMed ID: 12591969
[TBL] [Abstract][Full Text] [Related]
13. Mantle cell lymphoma in Taiwan: clinicopathological and molecular study of 21 cases including one cyclin D1-negative tumor expressing cyclin D2.
Chuang SS; Huang WT; Hsieh PP; Tseng HH; Campo E; Colomer D; Ye H; Lu CL; Chang HM; Cho CY; Huang SH; Lu YC; Wu JD
Pathol Int; 2006 Aug; 56(8):440-8. PubMed ID: 16872438
[TBL] [Abstract][Full Text] [Related]
14. Analysis of cyclin D1 expression by quantitative real-time reverse transcription-polymerase chain reaction in the diagnosis of mantle cell lymphoma.
Peghini PE; Fehr J
Am J Clin Pathol; 2002 Feb; 117(2):237-45. PubMed ID: 11863220
[TBL] [Abstract][Full Text] [Related]
15. Prognostic significance of BACH2 expression in diffuse large B-cell lymphoma: a study of the Osaka Lymphoma Study Group.
Sakane-Ishikawa E; Nakatsuka S; Tomita Y; Fujita S; Nakamichi I; Takakuwa T; Sugiyama H; Fukuhara S; Hino M; Kanamaru A; Soma T; Tsukaguchi M; Igarashi K; Kanakura Y; Aozasa K;
J Clin Oncol; 2005 Nov; 23(31):8012-7. PubMed ID: 16258099
[TBL] [Abstract][Full Text] [Related]
16. [Significance of soluble interleukin-2 receptor alpha chain in the management of patients with malignant lymphoma: a multi-center study].
Ohno H; Ishikawa T; Kitajima H; Nomura S; Suzuki T; Konishi H; Ohno Y; Onishi R; Konaka Y; Arima N; Doi S; Nasu K; Takahashi T; Tsudo M; Fukuhara S; Uchiyama T
Rinsho Ketsueki; 2002 Mar; 43(3):170-5. PubMed ID: 11979748
[TBL] [Abstract][Full Text] [Related]
17. Expression of a soluble decoy receptor 3 in patients with diffuse large B-cell lymphoma predicts clinical outcome.
Chang PM; Chen PM; Hsieh SL; Tzeng CH; Liu JH; Chiou TJ; Wang WS; Yen CC; Gau JP; Yang MH
Int J Oncol; 2008 Sep; 33(3):549-54. PubMed ID: 18695885
[TBL] [Abstract][Full Text] [Related]
18. Urinary pseudouridine in patients with lymphoma: comparison with other clinical parameters.
Masaki Y; Itoh K; Sawaki T; Karasawa H; Kawanami T; Fukushima T; Kawabata H; Wano Y; Hirose Y; Suzuki T; Sugai S; Umehara H
Clin Chim Acta; 2006 Sep; 371(1-2):148-51. PubMed ID: 16643879
[TBL] [Abstract][Full Text] [Related]
19. [Clinical significance of biological prognostic factors in non-Hodgkin lymphoma: analysis of serum and cell surface nm 23-H1 protein].
Niitsu N
Rinsho Ketsueki; 2003 Apr; 44(4):211-8. PubMed ID: 12784653
[No Abstract] [Full Text] [Related]
20. Diffuse large B-cell lymphoma with overexpression of cyclin e substantiates poor standard treatment response and inferior outcome.
Tzankov A; Gschwendtner A; Augustin F; Fiegl M; Obermann EC; Dirnhofer S; Went P
Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2125-32. PubMed ID: 16609025
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
